ConductScience.org, home

Paper17523705

Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany.

Koch H and 2 others. Clin Drug Investig, 2004. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany. Papers, record 17523705. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17523705

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany.
PubMed
Journal
Clin Drug Investig
PubMed
Year
2004
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.29
iCite
Revised in PubMed
2018-11-13
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Koch HH
2Landen HH
3Stauch KK

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117535055Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials : results of a two-year study.Clin Drug Investig2003https://conductscience.org/library/papers/17535055PubMed
210577109Fluoroquinolone resistance in Streptococcus pneumoniae.N Engl J Med1999https://conductscience.org/library/papers/10577109PubMed
311393351Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective.J Int Med Res2001https://conductscience.org/library/papers/11393351PubMed
411850164Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative.Int J Antimicrob Agents2002https://conductscience.org/library/papers/11850164PubMed
511052424Antibiotic therapy in acute exacerbations of chronic bronchitis.Semin Respir Infect2000https://conductscience.org/library/papers/11052424PubMed
610843981Infectious etiology of acute exacerbations of chronic bronchitis.Chest2000https://conductscience.org/library/papers/10843981PubMed
715006954Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.Chest2004https://conductscience.org/library/papers/15006954PubMed
811863209Quality of life in acute exacerbation of chronic bronchitis: results from a German population study.Respir Med2002https://conductscience.org/library/papers/11863209PubMed
99552014The value of antibiotics and the outcomes of antibiotic therapy in exacerbations of COPD.Chest1998https://conductscience.org/library/papers/9552014PubMed
1011389122Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.J Antimicrob Chemother2001https://conductscience.org/library/papers/11389122PubMed
119603117Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.Am J Respir Crit Care Med1998https://conductscience.org/library/papers/9603117PubMed
1210588312Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.J Antimicrob Chemother1999https://conductscience.org/library/papers/10588312PubMed
1311393350Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients.J Int Med Res2001https://conductscience.org/library/papers/11393350PubMed
1412740290Interpreting COPD prevalence estimates: what is the true burden of disease?Chest2003https://conductscience.org/library/papers/12740290PubMed
1511796368Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.Antimicrob Agents Chemother2002https://conductscience.org/library/papers/11796368PubMed
1612181400New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.N Engl J Med2002https://conductscience.org/library/papers/12181400PubMed
1710596683Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease.Eur Respir J1999https://conductscience.org/library/papers/10596683PubMed
1810795599Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.Eur J Clin Microbiol Infect Dis2000https://conductscience.org/library/papers/10795599PubMed
1910639387
Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.
Antimicrob Agents Chemother2000https://conductscience.org/library/papers/10639387PubMed
2011320449Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.Clin Infect Dis2001https://conductscience.org/library/papers/11320449PubMed

See all 33 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
22715866Moxifloxacin safety: an analysis of 14 years of clinical data.Drugs R D2012https://conductscience.org/library/papers/22715866PubMed
19419232Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.Drug Saf2009https://conductscience.org/library/papers/19419232PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17523705

GET https://conductscience.org/api/papers/v1/17523705/references?page=2